PBH Stock Analysis: Buy, Sell, or Hold?
PBH - Prestige Consumer Healthcare Inc.
$48.83
-0.07 (-0.14%)
▼
5d:
-0.06%
30d:
-0.61%
90d:
-13.65%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When PBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PBH trading at deep discount. Market pricing in -5.6% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: PBH trading at deep discount. Market pricing in -5.6% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$73.07
Based on 4.8% avg growth
INTRINSIC VALUE TODAY
$45.37
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBH is currently trading at $48.83, which is considered slightly high relative to its 30-day fair value range of $46.58 to $49.03. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.2) compared to its historical average (12.1). Remarkably, the market is currently pricing in an annual earnings decline of 5.6% over the next few years. This pessimistic expectation contrasts with the company's recent 12.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PBH is in a strong downtrend. Immediate support is located at $47.20, while resistance sits at $50.47.
Market Sentiment: PBH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $66.80 (+36.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PBH is in a strong downtrend. Immediate support is located at $47.20, while resistance sits at $50.47.
Market Sentiment: PBH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $66.80 (+36.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$46.58 -
$49.03
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
76.2%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 36.8% below Wall St target ($66.80)
Trading Range Analysis
30-Day Trading Range
$46.58 -
$49.03
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$47.20
Resistance Level
$50.47
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.20
Wall Street Target
$66.80
(+36.8%)
Revenue Growth (YoY)
-5.0%
Earnings Growth (YoY)
12.4%
Profit Margin
17.5%
Valuation Discount vs History
-5.6% cheaper
PE vs Historical
10.2 vs 12.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.6%
(market-implied from PE analysis)
1-Year Target
$46.10
(-6%)
2-Year Target
$43.51
(-11%)
3-Year Target
$41.08
(-16%)
3-Yr Target (if PE normalizes)
(PE: 10→12)
$48.74
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 5.5%)
$122.40
(+151%)
Base:
(SPY PE: 10.2, Growth: 5.5%)
$57.31
(+17%)
Bear:
(PE: 8.7, Growth: 5.5%)
$48.71
(0%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 12.51 | Current EPS (TTM): $3.91
Bull Case
$65.88
(+35%)
Analyst growth 22.5%, PE expands to 13.8
Base Case
$59.89
(+23%)
Market implied 22.5%, PE stable at 12.5
Bear Case
$33.25
(-32%)
Severe decline -20.0%, PE contracts to 10.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.2 to 12.1
Stabilization Target:
$57.94
(+18.7%)
PE Expansion Potential:
+18.7%
Share & Embed Analysis
Last updated: July 13, 2026 11:32 PM ET
Data refreshes hourly during market hours. Next update: 12:32 AM
Data refreshes hourly during market hours. Next update: 12:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Jeffrey Zerillo
SELL
1000 shares
2026-02-11
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
